NUTX Earnings

NUTX reported its earnings on 2026-02-18, showcasing a revenue of 0.00 against an estimate of 0.00, resulting in a 0% surprise. The EPS was 0, surpassing the expected 0 by 0% . The stock experienced a 0% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following NUTX's earnings announcement on 2026-02-18, the stock price moved by % on the day of the release. Over the subsequent five days, it saw a % change. Historically, NUTX's stock price tends to shift by an average of -3.90% in the 10 days leading up to earnings and +20.82% in the 10 days following, providing insight into potential market.

For 2025/Q4, analysts estimate NUTX’s annual revenue to reach 259.00M, while the EPS is projected at 6.00. These estimates reflect recent revisions, with revenue estimates revised Revenue Revise Upward by 16.89% and EPS estimates Revise Upward by 16.21% over the past three months, indicating analyst expectation in the company’s performance.

The correlation between NUTX's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were Revise Upward by 16.89%, while EPS estimates moved Revise Upward by 16.21% . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, NUTX's stock price typically moves by -3.90% in the 10 days before its earnings and +20.82% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of 6.00 and revenue of 259.00M.

The earnings call summary reveals strong financial performance with significant revenue growth, improved net income, and efficient cash management. Despite some concerns in the Q&A about delayed audited results and lower EBITDA margins, the company's overall trajectory is positive, driven by successful arbitration efforts, new hospital openings, and optimistic management guidance. The consistent revenue growth and robust cash position suggest a favorable stock reaction, likely in the positive range of 2% to 8%.